Skip to content

Hero image: A couple meeting a reproductive specialist after pregnancy loss with sensitive support

All insights

Fertility and Family Building

Recurrent Pregnancy Loss: A Structured Evaluation Without Unsupported Add-Ons

11 min readEvidence synthesis
Read the evidence

The question in focus

A compassionate, guideline-based guide to recurrent pregnancy loss definitions, evaluation, targeted treatment, prognosis and evidence limits.

Evidence at a glance

65 in 100

women with unexplained recurrent pregnancy loss who have a successful next pregnancy

This ACOG patient estimate is a population average, not an individual prediction. Prognosis changes with age, number and timing of losses, medical history and findings. [3]

Repeated Miscarriages

Definitions differ, but evaluation can begin after repeated loss

ESHRE and ASRM define recurrent pregnancy loss as two or more pregnancy losses, excluding confirmed ectopic and molar pregnancies. [1][6] RCOG uses three or more early miscarriages for its recurrent-miscarriage guideline. [4] These differences reflect evidence and health-system choices, not a judgment about the significance of any loss.

The clinical record should establish gestational timing, ultrasound or laboratory information where available, pathology or genetic results, maternal age, conception method and prior live births. Biochemical losses matter emotionally and may now be included in some definitions. The scope of evaluation should be individualized rather than determined by terminology alone.

  • Document every loss as accurately as records allow.
  • Include ectopic and molar history even when excluded from the definition.
  • Review second-trimester loss through an appropriate pathway.
  • Offer support without waiting for a threshold.

Most evaluations are targeted, not unlimited

Current guidelines support a detailed pregnancy, medical and family history; assessment of uterine anatomy; testing for antiphospholipid syndrome; and selected endocrine or genetic evaluation. [1][4] Products of conception testing and parental karyotypes may be considered according to the pattern, availability and how results would change counseling.

The probability of chromosomal loss rises with maternal age, but a random chromosomal event is not the person's fault. Uterine anomalies, antiphospholipid syndrome, poorly controlled diabetes and thyroid disease are among recognized contributors. More than half of people may still have no identified cause after evaluation. [3]

  • Assess the uterine cavity with an appropriate imaging method.
  • Use validated antiphospholipid testing and timing.
  • Check endocrine factors when clinically indicated.
  • Use genetic counseling to interpret relevant results.

Treatment should follow a supported cause

For recurrent loss associated with antiphospholipid syndrome, low-dose aspirin plus heparin during pregnancy can improve outcomes. [4] Correcting uncontrolled diabetes or thyroid disease is important for general and pregnancy health. Selected uterine septa may be considered for surgery, while benefits of surgery for other uterine findings can be less certain.

Progesterone is not a universal treatment for unexplained recurrent loss. RCOG recommends considering vaginal progesterone for women with recurrent miscarriage who develop bleeding in early pregnancy. [5] The exact indication matters. Treatment should not be generalized from a subgroup to everyone with prior loss.

  • Link each medicine to a documented indication.
  • Discuss benefits, harms and treatment timing.
  • Do not prescribe anticoagulation without an evidence-based reason.
  • Coordinate the next pregnancy plan before conception when possible.

Many commercial add-ons do not have proven benefit

Broad immune panels, natural-killer-cell testing, intralipid infusions, corticosteroids, empiric anticoagulation and many supplements are marketed to people seeking an explanation. ESHRE's guideline grades recommended and non-recommended investigations and treatments according to the available evidence. [1] Lack of an identified cause does not justify an intervention with uncertain benefit and known harms.

Routine preimplantation genetic testing for aneuploidy has not been shown to improve outcomes for every couple with unexplained recurrent miscarriage, and RCOG states evidence is insufficient for routine use. [5] IVF can still be appropriate for a separate fertility indication or specific genetic circumstance. The indication should be explicit.

  • Ask whether an intervention improves live birth, not a surrogate alone.
  • Request the guideline-supported indication.
  • Consider cost, delay and treatment burden as harms.
  • Distinguish fertility treatment from recurrent-loss treatment.

Prognosis is personal, but often better than feared

ESHRE recommends basing prognosis primarily on maternal age and the number of preceding losses. [2] Prior live birth, gestational timing and identified conditions can add context. A population estimate such as ACOG's successful-next-pregnancy figure should support a conversation, not become a promise or a reason to withhold evaluation.

Early access to ultrasound, a named contact and a plan for bleeding or pain can reduce uncertainty in the next pregnancy, even when they cannot prevent every loss. Supportive care should also include control of chronic conditions, folic acid, smoking and alcohol review, and evidence-based preconception care.

  • Ask for a prognosis using age and full pregnancy history.
  • Agree when and where early pregnancy review will occur.
  • Plan urgent assessment for pain or heavy bleeding.
  • Avoid assigning blame to stress, exercise or ordinary activity.

Grief care is part of medical care

Recurrent loss can produce grief, anxiety, depression, trauma symptoms and strain between partners who grieve differently. ACOG emphasizes that miscarriage is almost never caused by something the person did or did not do. [3] Clear language, prompt results, continuity and options for counseling or peer support are clinical quality measures.

The next decision may be to try again, pause, pursue fertility treatment, use donor gametes, consider another family-building route or stop treatment. None is universally correct. A high-quality service protects informed choice while resisting unsupported tests and treatments that exploit urgency.

  • Screen for depression, anxiety and traumatic distress.
  • Include partners and support people with consent.
  • Provide written results and a next-step plan.
  • Respect a decision not to pursue another pregnancy.

What the evidence cannot yet answer

  • Professional definitions differ in the number and type of losses included.
  • Many associations are observational, and an identified finding may not be causal.
  • A substantial proportion of recurrent loss remains unexplained after guideline-based evaluation.
  • Population live-birth estimates cannot predict an individual's next pregnancy.

Questions worth taking into care

  1. Which definition and guideline is my service using?
  2. Which tests are recommended for my specific loss pattern?
  3. How would each result change treatment or prognosis?
  4. Which proposed treatments improve live birth in people like me?
  5. What medical and emotional support is planned for the next pregnancy?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    Guideline on the Management of Recurrent Pregnancy Loss

    European Society of Human Reproduction and Embryology · 2023

  2. [2]
  3. [3]
    Repeated Miscarriages

    American College of Obstetricians and Gynecologists · 2026

  4. [4]
    Recurrent Miscarriage: Patient Information

    Royal College of Obstetricians and Gynaecologists · 2023

  5. [5]
    Recurrent Miscarriage: Green-top Guideline No. 17

    Royal College of Obstetricians and Gynaecologists · 2023

  6. [6]
    Recurrent Pregnancy Loss: A Committee Opinion

    American Society for Reproductive Medicine · 2026

Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.